Search Technologies
Displaying 71 - 80 of 84 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Inhibitors of S100 Proteins for the Treatment of Cancer and Other Diseases Involving Uncontrolled Cell Growth via an S100-Dependent Pathway
Published Wednesday, May 28, 2014Small molecules have been identified, using rational drug design, that bind to a site on S100 proteins, rendering S100 incapable of inactivating p53 tumor suppressor protein. Inhibitors of S100 thus restore tumor suppressor activity of the p53 protein by inhibiting the S100-p53 interaction. Inhibitors are specific to different members of the...
Investigator(s): David Weber, Joseph Markowitz, France Carrier
Categories: Diagnostics, Therapeutics, Small molecules
Keyword(s): tumor, cancer, S100 proteins, research tools
Docket: DW-2002-041
-
Inhibitors of Extracellular Signal-Regulated Kinase (ERK) regulated signaling pathways
Published Wednesday, May 28, 2014This technology is a set of novel ATP-independent, extracellular signal-regulated kinase (ERK) inhibitors that have the potenital to provide specific targeting compared to existing ERK1/2 inhibitors. The lead ATP-independent ERK inhibitor candidates, interact with specific ERK substrate...
Investigator(s): Paul Shapiro, Stephen Fletcher, Alex MacKerell
Categories: Therapeutics, Small molecules
Keyword(s): Signal-Regulated Kinase, ERK
Docket: PS-2013-025,PS-2013-054
-
Inhibitors of Cell Migration and Shape Changes by Inhibiting Cortactin and HS-1 Mediated Actin Polymerization
Published Wednesday, May 28, 2014The present invention is a novel approach to suppress metastasis by targeting cortactin (or HS-1), an actin -associated protein. Cortactin is overexpressed in breast cancer and head and neck carcinomas where it plays a major role in tumor progression by promoting metastasis. Preventing binding of cortactin (or HS-1) to Arp2/3 blocks actin...
Investigator(s): Xi Zhan, Takehito Uruno
Categories: Therapeutics, Small molecules
Keyword(s): neck carcinomas, head carcinomas, cancer
Docket: XZ-2005-108
-
TLR Inhibitors for Treatment of Influenza, Cancer, Allergy, Inflammation and Prevention of Endotoxic Shock
Published Wednesday, May 28, 2014The Toll-like receptors (TLRs) play a vital role in eradicating pathogenic microbial infections, eliminating necrotic host cells and enhancing tissue repair in the host. On the flip side, chronic TLR activation leads to inflammatory disease and “systemic” activation of TLRs may lead to death. ...
Investigator(s): Vladimir Toshchakov
Categories: Research Tools, Antibodies, & Reagents, Platforms, Therapeutics, Biologics
Keyword(s): TLR, decoy peptides, inflammation, cancer, microbial infections, immune disorders, allergy, endotoxic shock, TRAM, TRIF, TIRAP and MyD88
Docket: VT-2012-029 VT-2012-052
-
Inhibition of Breast Cancer Metastases using Natural Extracts from Colocasia Esculenta (Taro).
Published Wednesday, May 28, 2014Studies link breast cancer, the second leading cause of cancer-related mortality in US women, with the occurrence of metastatic disease and spread. However, the majority of current therapies focus on the treatment of solid tumors with very little focus on targeting the metastatic process. Due to the significant correlation of secondary tumors...
Investigator(s): Namita Kundu, Amy Fulton
Categories: Therapeutics, Biologics, Natural Compounds
Keyword(s): breast cancer, cancer
Docket: NK-2009-001
-
IL-25 treatment of obesity and metabolic disorders
Published Tuesday, May 27, 2014Obesity is associated with chronic low grade inflammation in adipose tissues, mainly due to the accumulated immune cells (Th1/Th17 cells, macrophages etc.) that release pro inflammatory cytokines into the system. These cytokines contribute to development of the “metabolic syndrome.” IL-25 is an important regulator in the...
Investigator(s): Aiping M. Zhao, Terez Shea-Donohue
Categories: Therapeutics, Biologics
Keyword(s): IL-25, Biologic, Therapeutic
Docket: AZ-2011-020
-
Disruption of the microtubule network as a therapeutic intervention in the muscular dystrophies
Published Tuesday, May 27, 2014Across several muscular myopathies, such as Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, and dysferlinopathies, intercellular signaling cascades such as reactive oxygen signaling (ROS) and calcium (Ca2+) are enhanced and contribute to the onset and pathogenic progression of the myopathy. The discovery of the...
Investigator(s): Christopher Ward, Ramzi Khairallah
Categories: Research Tools, Antibodies, & Reagents, Therapeutics, Biologics, Engineering, Bioengineering
Keyword(s): musculoskeletal, rare disease, muscular dystrophy
Docket: CW-2012-040
-
Defensin-like molecules as novel antimicrobial agents
Published Tuesday, May 27, 2014The ever increasing emergence of many pathogenic strains of bacteria resistant to commonly used antibiotics is a rapidly growing concern in public health and new classes of antimicrobial agents are desperately needed. One approach that has gained popularity recently is to study naturally-occurring antimicrobial peptides that have the advantage...
Investigator(s): Erik de Leeuw, Alexander MacKerell
Categories: Diagnostics, Therapeutics
Docket: ED-2012-088, ED-2010-066
-
Defect-free dendrimer synthesis through proportionate branching
Published Tuesday, May 27, 2014Dendrimers are nanoparticles of synthetic monomers with applications in commercial paints, blood substitutes, nanomaterials, sensor technology. Dendrimers are also building blocks for targeted drug or gene delivery. The dendrimers open architecture forms hollow cavities within the branches that can encapsulate molecules such as drugs or...
Investigator(s): Bruce Yu, Xuyi Yue
Categories: Imaging devices, Diagnostics, Platforms, Therapeutics, Engineering, Biomaterials
Docket: BY-2012-068
-
Clostridium difficile Type IV Pilin As New Target for Vaccine, Therapeutics and Diagnostics
Published Tuesday, May 27, 2014Type IV pilin proteins are extracellular and easily accessible to the host immune system, as well as being important for initial colonization and biofilm formation. Thus, these proteins present excellent targets for vaccines to prevent pathogen colonization. Neutralizing antibodies directed against pili could lead to...
Investigator(s): Michael Donnenberg
Categories: Diagnostics, Therapeutics, Vaccines
Keyword(s): vaccine
Docket: MD-2008-081